Faleiro, InêsApolónio, JoanaPrice, Aryeh J.De Mello, Ramon AndradeRoberto, VâniaTabori, UriCastelo-Branco, Pedro2019-11-202019-11-202017-101479-66941744-8301http://hdl.handle.net/10400.1/12962Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. Discussion: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. Conclusion: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.engTelomeraseExpressionCarcinomajournal article10.2217/fon-2017-0167